News and Press Releases
Press releases
Theralase® Announces $4 Million Brokered LIFE Offering
Press Release, GLP, RCC, rutherrin, Ruvidar, TSXVTMX NewsfileMay 5, 2026 7:10 PM EDT THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario–(Newsfile Corp. – May 5, 2026) – Theralase® Technologies Inc. (TSXV: TLT)...
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Press ReleaseTMX Newsfile | May 4, 2026 5:22 PM EDT Toronto, Ontario–(Newsfile Corp. – May 4, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the ...
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Press ReleaseTMX Newsfile | Apr 13, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – April 13, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to ...
Theralase(R) Closes $CAN 2.66 Million Financing
Press ReleaseTMX Newsfile | Apr 10, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – April 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to ...
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Press ReleaseTMX Newsfile | Mar 17, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – March 17, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company, dedicated to...
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Press ReleaseTMX Newsfile | Mar 10, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – March 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to ...
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Press ReleaseTMX Newsfile | Mar 9, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – March 9, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to th...
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
Press ReleaseTMX Newsfile | Mar 2, 2026 7:00 AM EST Theralase(R) Demonstrates Additive Anti-Cancer Effect in Bladder Cancer In-Vitro Model when Light-Activated Ruvidar(R) is Combined with Interferon Toronto, Ontario–(Newsfile Corp. – March 2, 2026) –...
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Press ReleaseTMX Newsfile | Feb 20, 2026 7:00 AM EST This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past. Toronto, Ontario–(Newsfile Corp. – February 20, 2026) – Theralase® Tec...
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
Press ReleaseTMX Newsfile | Feb 10, 2026 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – February 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated ...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
